Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Gynecology

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 102 articles:
HTML format



Single Articles


    February 2024
  1. BANI MA, Maulard A, Morice P, Chargari C, et al
    Integration of the Molecular Classification of Endometrial Carcinoma to Select Patients for Fertility Sparing Strategies.
    Anticancer Res. 2024;44:445-452.
    PubMed     Abstract available


  2. CARMASSI C, Pedrinelli V, Fantasia S, Andreoli D, et al
    Post-traumatic Stress and Depressive Symptoms in Women With Ovarian Cancer 3-6 Months After Diagnosis.
    Anticancer Res. 2024;44:829-838.
    PubMed     Abstract available


  3. ACS M, Herold Z, Neumann L, Slowik P, et al
    Surgical Treatment and Outcome of Ovarian Cancer Patients With Liver Metastases: Experience of a Tertiary Hepatic and Peritoneal Surface Malignancy Center.
    Anticancer Res. 2024;44:731-741.
    PubMed     Abstract available


  4. BRAUTIGAM K, Schmidt T, Baur M, Tauber N, et al
    Prevalence of PD-L1 in Cervical Cancer Patients and the Potential for Combining an Immune Checkpoint Inhibitor With Lenvatinib.
    Anticancer Res. 2024;44:503-510.
    PubMed     Abstract available


  5. CHECK JH, Check DL, DO TP, Srivastava M, et al
    Significant Palliative Benefits Following Therapy With Mifepristone for Advanced Treatment Resistant Small Cell Lung Cancer.
    Anticancer Res. 2024;44:659-664.
    PubMed     Abstract available


  6. LEE O, Yoon SK, Yoon SJ, Kim H, et al
    Pancreatic Metastasectomy for Secondary Malignancy of the Pancreas: A Single-institution Experience.
    Anticancer Res. 2024;44:703-710.
    PubMed     Abstract available


  7. KIM Y, Ajiki T, Ueda Y, Yoshida Y, et al
    Reappraisal of a Renovated Cell-free and Concentrated Ascites Reinfusion Therapy for Malignant Ascites.
    Anticancer Res. 2024;44:613-619.
    PubMed     Abstract available


    January 2024
  8. NICHOLS M, Kesaria A, Spencer HJ, Williams HR, et al
    Opioid Use in Patients With Cervical Cancer at a Tertiary Academic Medical Center.
    Anticancer Res. 2024;44:151-155.
    PubMed     Abstract available


  9. OSHIMA T, Hashimoto I, Hiroshima Y, Kimura Y, et al
    Clinical Significance of Pregnancy Zone Protein Expression in Patients With Locally Advanced Gastric Cancer After Curative Resection.
    Anticancer Res. 2024;44:369-374.
    PubMed     Abstract available


    December 2023
  10. KUUSINIEMI E, Karihtala P, Puistola U, Ahtikoski A, et al
    Oxidative Stress-regulating Enzymes and Endometrial Cancer Survival in Relation to Metformin Intake in Diabetic Patients.
    Anticancer Res. 2023;43:5545-5554.
    PubMed     Abstract available


  11. VIALE M, Bertola N, Panebianco R, Vecchio G, et al
    Terpyridine Functionalized Cyclodextrin Nanoparticles as Carriers for Doxorubicin: Analysis of In Vitro Antiproliferative Activity.
    Anticancer Res. 2023;43:5409-5414.
    PubMed     Abstract available


  12. ISODA L, Sonoda-Fukuda E, Fujino H, Takarada T, et al
    Therapeutic Efficacy of Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors for Human Ovarian Cancer.
    Anticancer Res. 2023;43:5311-5317.
    PubMed     Abstract available


    November 2023
  13. YOO SS, Katsarakes P, Gashi J, Kim E, et al
    Non-thermal Acoustic Enhancement of Chemotherapeutic Effects of Cisplatin on Xenografted Cervical Cancer in Mice.
    Anticancer Res. 2023;43:4793-4800.
    PubMed     Abstract available


  14. SZEWCZUK W, Szewczuk O, Czajkowski K, Waledziak M, et al
    HPV16 E6 Gene Transcripts in Primary Type II Endometrial Carcinomas.
    Anticancer Res. 2023;43:5083-5088.
    PubMed     Abstract available


  15. HUANG YN, Chen SC, Chen JC, Liu KW, et al
    Elucidating the Cancer Phenotype in Turner Syndrome: A 20-Year Observational Cohort Study.
    Anticancer Res. 2023;43:5073-5081.
    PubMed     Abstract available


  16. HUANG X, Wu Z, Xiao C, Chen XI, et al
    E2F7/RAD51AP1 Axis Inhibits Endometrial Cancer Sensitivity to 5-FU via the Fatty Acid Metabolic Pathway.
    Anticancer Res. 2023;43:4905-4914.
    PubMed     Abstract available


    October 2023
  17. HASHIMOTO K, Kawakami K, Yokokawa T, Shibata N, et al
    Serum Creatinine Elevation as a Risk Factor for Niraparib-induced Hematologic Toxicity.
    Anticancer Res. 2023;43:4533-4541.
    PubMed     Abstract available


  18. SAILLANT A, Rasclard M, Gaume JB, Souchaud O, et al
    A Case of Anti-3-hydroxy-3-methylglutaryl-coenzyme A Reductase Myopathy Associated With Advanced Cervical Carcinoma.
    Anticancer Res. 2023;43:4723-4727.
    PubMed     Abstract available


  19. LIAKOU C, Pandraklakis A, LA Russa MC, Turnbull H, et al
    Interval Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Ovarian Cancer: Report of a Single-center Experience.
    Anticancer Res. 2023;43:4593-4599.
    PubMed     Abstract available


  20. PARK S, Cho Y, Kim HS
    Mesonephric-like Adenocarcinoma of the Uterine Corpus: Clinicopathological and Prognostic Significance of L1 Cell Adhesion Molecule (L1CAM) Over-expression.
    Anticancer Res. 2023;43:4559-4571.
    PubMed     Abstract available


  21. MONTI E, Matozzo CMM, Cetera GE, DI Loreto E, et al
    Correlation Between Colposcopic Patterns and Histological Grade of Vaginal Intraepithelial Neoplasia: A Retrospective Cohort Study.
    Anticancer Res. 2023;43:4637-4642.
    PubMed     Abstract available


    September 2023
  22. HOLSTER T, Urpilainen E, Paavonen J, Puistola U, et al
    Immunological Markers of Chlamydia trachomatis Infection in Epithelial Ovarian Cancer.
    Anticancer Res. 2023;43:4037-4043.
    PubMed     Abstract available


  23. PSILOPATIS I, Garmpis N, Garmpi A, Vrettou K, et al
    Liver Cancer and Pregnancy: A Review of the Literature.
    Anticancer Res. 2023;43:3861-3869.
    PubMed     Abstract available


  24. CAGLAYAN A, Rabbani RD, Sanchez E, Choi S, et al
    Gestational Renal Cell Cancer - An Update.
    Anticancer Res. 2023;43:3871-3880.
    PubMed     Abstract available


    August 2023
  25. SHIBAHARA M, Kurita T, Murakami M, Harada H, et al
    Association of UBE2L6 and ABCB6 Expression With Platinum Resistance in Serous Ovarian Carcinoma.
    Anticancer Res. 2023;43:3787-3792.
    PubMed     Abstract available


  26. AKAZAWA M, Hashimoto K
    Preliminary Results of Deep Learning Approach for Preoperative Diagnosis of Ovarian Cancer Based on Pelvic MRI Scans.
    Anticancer Res. 2023;43:3817-3821.
    PubMed     Abstract available


  27. XIE Y, Kong W, Luo D, Chen S, et al
    Ovarian Clear Cell Carcinoma: Genomic Characterization, Pathogenesis and Targeted Therapy.
    Anticancer Res. 2023;43:3401-3410.
    PubMed     Abstract available


  28. MATSUOKA H, Nakamura K, Yorimitsu M, Ogawa M, et al
    Relationship Between Hematological Toxicities During Maintenance Treatment and During Chemotherapy Before Maintenance Treatment in Patients With Platinum-sensitive Relapsed Ovarian Cancer.
    Anticancer Res. 2023;43:3653-3658.
    PubMed     Abstract available


  29. KUBO-KANEDA M, Kondo E, Okugawa T, Yamawaki T, et al
    Positive Ascites Cytology, Postoperative Chemotherapy and Prognosis of Stage I Ovarian Clear Cell Carcinoma.
    Anticancer Res. 2023;43:3799-3805.
    PubMed     Abstract available


  30. KOROSUE M, Nakagawa K, Yoshiyasu K, Narita S, et al
    Medroxyprogesterone as the Initial Systemic Treatment of Recurrent Endometrial Cancer: A Single Institutional Study.
    Anticancer Res. 2023;43:3693-3699.
    PubMed     Abstract available


    July 2023
  31. STUEBS FA, Koch MC, Dietl AK, Schulmeyer CE, et al
    Management of Cervical Intraepithelial Neoplasia in Pregnant Women.
    Anticancer Res. 2023;43:3153-3158.
    PubMed     Abstract available


  32. LIM H, Kim SI, Kim EN, Lee M, et al
    Tissue Expression and Prognostic Role of CXCL12 and CXCR4 in High-grade Serous Ovarian Carcinoma.
    Anticancer Res. 2023;43:3331-3340.
    PubMed     Abstract available


  33. HIRAI R, Ohta T, Igari M, Kumazaki YU, et al
    Optimal Number of Needle Applicators Inserted in Combined Intracavitary and Interstitial Brachytherapy for Cervical Cancer.
    Anticancer Res. 2023;43:3265-3271.
    PubMed     Abstract available


  34. FUKUDA T, Noda T, Uchikura E, Awazu Y, et al
    Real-world Efficacy and Safety of Bevacizumab for Advanced or Recurrent Mullerian Cancer: A Single-institutional Experience.
    Anticancer Res. 2023;43:3097-3105.
    PubMed     Abstract available


    June 2023
  35. SEKINE M, Koh I, Nakamoto K, Nosaka S, et al
    Selective Inhibition of L-type Amino Acid Transporter 1 Suppresses Cell Proliferation in Ovarian Clear Cell Carcinoma.
    Anticancer Res. 2023;43:2509-2517.
    PubMed     Abstract available


  36. TAKAGI S, Onishi T, Takashima T, Shibahara K, et al
    Acquired AKT-inhibitor Resistance Is Mediated by ATP-binding Cassette Transporters in Endometrial Carcinoma.
    Anticancer Res. 2023;43:2501-2507.
    PubMed     Abstract available


    May 2023
  37. MIYASAKA Y, Yoshimoto Y, Ando K, Murata K, et al
    CD8-positive Tumor-infiltrating Lymphocytes and Prognosis in Radiotherapy for Uterine Cervical Squamous Cell Carcinoma.
    Anticancer Res. 2023;43:2077-2084.
    PubMed     Abstract available


  38. LOPACINSKA-JOERGENSEN J, Oliveira DVNP, Poulsen TS, Hoegdall CK, et al
    Somatic Variants in DNA Damage Response Genes in Ovarian Cancer Patients Using Whole-exome Sequencing.
    Anticancer Res. 2023;43:1891-1900.
    PubMed     Abstract available


  39. UEDA T, Tsubamoto H, Takimoto Y, Isono-Taniguchi R, et al
    Comprehensive Genomic Profiling Detects Hereditary Cancers and Confers Survival Advantage in Patients With Gynaecological Cancers.
    Anticancer Res. 2023;43:2091-2101.
    PubMed     Abstract available


    April 2023
  40. DORMAN K, Zhang D, Kunz WG, Angele M, et al
    Treatment of Mediastinal Endometrial Carcinoma Developed from Extragenital Endometriosis and Simultaneous Rectal Adenocarcinoma in a 55-year-old Woman.
    Anticancer Res. 2023;43:1857-1861.
    PubMed     Abstract available


  41. CHINCZEWSKI L, Feldhaus FW, Schmitt W, Braicu I, et al
    Complete Response to Immune Checkpoint Inhibition in a Platinum Resistant Primary Ovarian Cancer Patient With Lynch Syndrome: A Case Report and Review of the Literature.
    Anticancer Res. 2023;43:1655-1662.
    PubMed     Abstract available


  42. GADDUCCI A, Simonetti E, Cosio S, Fanucchi A, et al
    Positive p16 Immunostaining Is an Independent Prognostic Variable for Disease-free Survival and Overall Survival in Patients With Squamous Cell Carcinoma of the Vulva Treated With Radical Surgery and Inguinofemoral Lymphadenectomy: An Italian Single C
    Anticancer Res. 2023;43:1643-1648.
    PubMed     Abstract available


  43. MIYOSHI AI, Ueda Y, Kurita T, Kimura T, et al
    Recent Advances in the Management of Small Cell Carcinoma of the Uterine Cervix.
    Anticancer Res. 2023;43:1397-1405.
    PubMed     Abstract available


  44. KIM H, Kim HS
    Mesonephric-like Adenocarcinoma of the Uterine Corpus: Comparison Between Mismatch Repair Protein Immunostaining and Microsatellite Instability Testing.
    Anticancer Res. 2023;43:1785-1795.
    PubMed     Abstract available


    March 2023
  45. ABE M, Shoji T, Chiba Y, Takatori E, et al
    Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study.
    Anticancer Res. 2023;43:1265-1272.
    PubMed     Abstract available


    February 2023
  46. TAKIMOTO Y, Tsubamoto H, Taniguchi R, Sakata K, et al
    Itraconazole Repolarizes Tumor-associated Macrophages and Suppresses Cervical Cancer Cell Growth.
    Anticancer Res. 2023;43:569-580.
    PubMed     Abstract available


  47. MARTIN-SALAMANCA B, Erasun D, Llorca J, Schneider J, et al
    Ki67 and E-cadherin Are Independent Predictors of Long-term Survival in Endometrial Carcinoma.
    Anticancer Res. 2023;43:683-687.
    PubMed     Abstract available


  48. BOURIEN H, Lefevre LB, Mouret-Reynier MA, Asselain B, et al
    Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study.
    Anticancer Res. 2023;43:653-662.
    PubMed     Abstract available


    January 2023
  49. PISTOLESI S, Fanelli GN, Giudice F, Garbini F, et al
    Cervical Adenocarcinoma: A Still Under-investigated Malignancy.
    Anticancer Res. 2023;43:53-58.
    PubMed     Abstract available


  50. LALISCIA C, Gadducci A, Coccia N, Mattioni R, et al
    Lymph-vascular Space Involvement and/or p53 Overexpression Correlated With the Clinical Outcome of Early-stage Endometrial Cancer Patients Treated With Adjuvant Vaginal Brachytherapy.
    Anticancer Res. 2023;43:149-156.
    PubMed     Abstract available


    December 2022
  51. RALSER DJ, Condic M, Egger E, Koensgen D, et al
    Evaluation of the Diagnostic Potential of Circulating MicroRNAs miR-1 and miR-21 in Patients With Ovarian Cancer.
    Anticancer Res. 2022;42:5839-5845.
    PubMed     Abstract available


    November 2022
  52. BIENKOWSKA-TOKARCZYK A, Manda-Handzlik A, Gawrychowski K, Demkow U, et al
    The Activity of Vitamin C Against Ovarian Cancer Cells Is Enhanced by Hyperthermia.
    Anticancer Res. 2022;42:5365-5383.
    PubMed     Abstract available


    October 2022
  53. EGGER E, Merker F, Ralser DJ, Condic M, et al
    Tumor Load Matters - the Peritoneal Cancer Index in Patients With High-grade Serous Ovarian Cancer.
    Anticancer Res. 2022;42:4825-4831.
    PubMed     Abstract available


  54. KISE S, Arakaki Y, Kudaka W, Ariga T, et al
    Sarcopenia Is an Independent Prognostic Factor for Squamous Cell Carcinoma of the Cervix Treated With Concurrent Chemoradiotherapy.
    Anticancer Res. 2022;42:4887-4893.
    PubMed     Abstract available


  55. KIM JY, Park H, Lee DW, Kim MJ, et al
    Prognostic Significance of Clinical Factors Including BRCA Mutation in Epithelial Ovarian, Peritoneal, Fallopian Tube Cancer.
    Anticancer Res. 2022;42:4945-4954.
    PubMed     Abstract available


  56. LEE J, Hong DG
    Comparison of Survival Outcomes Based on Pre-treatment Pleural Effusion in Advanced Epithelial Ovarian Cancer.
    Anticancer Res. 2022;42:4937-4943.
    PubMed     Abstract available


  57. GADDUCCI A, Cosio S, Lippolis PV
    Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists.
    Anticancer Res. 2022;42:4659-4665.
    PubMed     Abstract available


    September 2022
  58. LEE Y, Bae H, Kim HS
    Endocervical Adenocarcinoma: Comprehensive Histological Review and Re-classification of 123 Consecutive Cases According to the Updated World Health Organization Classification of Female Genital Tumors.
    Anticancer Res. 2022;42:4627-4639.
    PubMed     Abstract available


  59. TATSUKI S, Shoji T, Abe M, Tomabechi H, et al
    Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study.
    Anticancer Res. 2022;42:4603-4610.
    PubMed     Abstract available


  60. OKAMOTO K, Nakamura K, Haraga J, Masuyama H, et al
    Molecular Characteristics of Metastatic Lesions Have Superior Prognostic Impact on Endometrial Cancer.
    Anticancer Res. 2022;42:4535-4543.
    PubMed     Abstract available


  61. GADDUCCI A, Cosio S
    Screening for Ovarian Cancer in the General Population: State of Art and Perspectives of Clinical Research.
    Anticancer Res. 2022;42:4207-4216.
    PubMed     Abstract available


  62. ZEITLER C, Fuderer L, Schmitz K, Arora R, et al
    Pheochromocytoma Turned Malignant During Pregnancy in a Patient With Neurofibromatosis Type I - A Case Report and Systematic Review of the Current Literature.
    Anticancer Res. 2022;42:4647-4656.
    PubMed     Abstract available


  63. FERINI G, Valenti V, Viola A, Umana GE, et al
    First-ever Clinical Experience With Magnetic Resonance-based Lattice Radiotherapy for Treating Bulky Gynecological Tumors.
    Anticancer Res. 2022;42:4641-4646.
    PubMed     Abstract available


    August 2022
  64. YOTSUMOTO F, Sanui A, Ito T, Miyahara D, et al
    Cumulative Summation Analysis of Learning Curve for Robotic-assisted Hysterectomy in Patients With Gynecologic Tumors.
    Anticancer Res. 2022;42:4111-4117.
    PubMed     Abstract available


  65. OGATA N, Toh U, Sudou T, Ogata S, et al
    Efficacy and Safety of Monthly Minodronate Therapy in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors.
    Anticancer Res. 2022;42:4139-4143.
    PubMed     Abstract available


  66. YOKOYAMA Y, Kubo-Kaneda M, Sunada K, Teishikata Y, et al
    Adverse Events Associated With Long-term Treatment of Epithelial Ovarian Cancer With Bevacizumab and Chemotherapy.
    Anticancer Res. 2022;42:4165-4171.
    PubMed     Abstract available


    July 2022
  67. VEYSSIERE H, Aldarazi G, Molnar I, Durando X, et al
    Nestin as a Prognostic Biomarker in High-grade Epithelial Ovarian Cancer Treated by Neoadjuvant Chemotherapy.
    Anticancer Res. 2022;42:3583-3594.
    PubMed     Abstract available


  68. RAJHA A, Piso P, Halmy L, Panczel I, et al
    Rare Histologies and Infrequent Indications for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Anticancer Res. 2022;42:3681-3692.
    PubMed     Abstract available


  69. IMAMURA A, Oike T, Sato H, Yoshimoto Y, et al
    Comparative Analysis of the Antitumor Immune Profiles of Paired Radiotherapy-naive and Radiotherapy-treated Cervical Cancer Tissues.
    Anticancer Res. 2022;42:3341-3348.
    PubMed     Abstract available


  70. TATE S, Nishikimi K, Matsuoka A, Otsuka S, et al
    Highly Aggressive Surgery Benefits in Patients With Advanced Ovarian Cancer.
    Anticancer Res. 2022;42:3707-3716.
    PubMed     Abstract available


    June 2022
  71. GIVENS NT, Zhao L, Zhu Z, Lequio M, et al
    Mangosteen Inhibits Growth and Survival of Cervical Cancer Cells.
    Anticancer Res. 2022;42:2903-2909.
    PubMed     Abstract available


  72. UNO A, Yamamoto S, Iihara H, Fujii H, et al
    Control and Risk Factors of Nausea and Vomiting in Patients With Cervical Cancer Receiving Radiotherapy.
    Anticancer Res. 2022;42:3117-3123.
    PubMed     Abstract available


  73. OOYAMA T, Shimoji Y, Nakasone T, Arakaki Y, et al
    Effects of Pegylated Liposomal Doxorubicin and CA125 Level Variability Analysis in Platinum-refractory/resistant Recurrent Ovarian Cancer.
    Anticancer Res. 2022;42:3017-3022.
    PubMed     Abstract available


    May 2022
  74. TATE S, Nishikimi K, Matsuoka A, Otsuka S, et al
    Bevacizumab-based Salvage Chemotherapy Improves Survival Outcomes for Patients With Brain Metastasis from Ovarian Cancer.
    Anticancer Res. 2022;42:2637-2644.
    PubMed     Abstract available


  75. ASP M, Malander S, Bengtsson J, Sartor H, et al
    Prognostic Value of Peritoneal Cancer Index After Complete Cytoreductive Surgery in Advanced Ovarian Cancer.
    Anticancer Res. 2022;42:2541-2551.
    PubMed     Abstract available


  76. MAGKANA M, Mentzelopoulou P, Magkana E, Pampanos A, et al
    p16/Ki-67 Dual Staining Is a Reliable Biomarker for Risk Stratification for Patients With Borderline/Mild Cytology in Cervical Cancer Screening.
    Anticancer Res. 2022;42:2599-2606.
    PubMed     Abstract available


    April 2022
  77. AN J, Oh HE, Kim H, Lee JH, et al
    Significance of Altered Fatty Acid Transporter Expressions in Uterine Cervical Cancer and Its Precursor Lesions.
    Anticancer Res. 2022;42:2131-2137.
    PubMed     Abstract available


  78. GADDUCCI A, Cosio S, Landoni F, Lissoni AA, et al
    Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study.
    Anticancer Res. 2022;42:2017-2022.
    PubMed     Abstract available


  79. MITSOPOULOS V, Innamaa A, Lippiatt J, Collins S, et al
    Differences in Patterns of Recurrence Between Primary and Interval Debulking Surgery for Advanced Ovarian Cancer.
    Anticancer Res. 2022;42:2003-2008.
    PubMed     Abstract available


  80. ADDLEY S, McGowan M, Asher V, Bali A, et al
    Lactate Is a Reliable Predictor of ICU Length of Stay Following Ultra-radical Ovarian Cancer Surgery.
    Anticancer Res. 2022;42:1979-1986.
    PubMed     Abstract available


  81. SHORAKA M, Carbajal-Mamani SL, Dideban B, Zarrinpar A, et al
    Clinical Utility and Cost of Postoperative Hemoglobin Level Testing Following Robotic-assisted Hysterectomy for Endometrial Cancer.
    Anticancer Res. 2022;42:1893-1898.
    PubMed     Abstract available


  82. ABOBAKER S, Kulbe H, Taube ET, Darb-Esfahani S, et al
    Polycomb Protein BMI-1 as a Potential Therapeutic Target in Mucinous Ovarian Cancer.
    Anticancer Res. 2022;42:1739-1747.
    PubMed     Abstract available


  83. OHASHI K, Li TS, Miura S, Hasegawa Y, et al
    Biological Differences Between Ovarian Cancer-associated Fibroblasts and Contralateral Normal Ovary-derived Mesenchymal Stem Cells.
    Anticancer Res. 2022;42:1729-1737.
    PubMed     Abstract available


    March 2022
  84. HECKING T, Thiesler T, Halbe J, Otten L, et al
    Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer.
    Anticancer Res. 2022;42:1367-1376.
    PubMed     Abstract available


    February 2022
  85. DELRUE C, Vanwalleghem L, Paepe P, Trappen PV, et al
    Stratified Mucin-producing Intraepithelial Lesions of the Cervix: Clinical Diversity of Cases and Literature Review.
    Anticancer Res. 2022;42:1175-1180.
    PubMed     Abstract available


  86. MATSUDA R, Sato F, Kotsugi M, Morimoto T, et al
    Awake Surgery for Local Recurrence of Brain Metastasis in the Precentral Gyrus After Fractionated Stereotactic Radiotherapy: A Technical Case Report.
    Anticancer Res. 2022;42:1151-1155.
    PubMed     Abstract available


  87. SHIBATA N, Kawakami K, Hisanori S, Kobayashi K, et al
    Investigation of Hypersensitivity Reactions in Carboplatin Desensitization Therapy.
    Anticancer Res. 2022;42:1091-1097.
    PubMed     Abstract available


  88. ALEXOPOULOS A, Karanikiotis C, Ardavanis A, Boukovinas I, et al
    Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 "MELPOMENI" s
    Anticancer Res. 2022;42:1031-1041.
    PubMed     Abstract available


  89. DOBILAS A, Thalin C, Wallen H, Borgfeldt C, et al
    Circulating Markers of Neutrophil Extracellular Traps (NETs) in Patients With Ovarian Tumors.
    Anticancer Res. 2022;42:965-971.
    PubMed     Abstract available


  90. GADDUCCI A, Simonetti E, Mezzapesa F, Cosio S, et al
    Computed Tomography-assessed Skeletal Muscle Index and Skeletal Muscle Radiation Attenuation in Patients With Ovarian Cancer Treated With Primary Surgery Followed by Platinum-based Chemotherapy: A Single-center Italian Study.
    Anticancer Res. 2022;42:947-954.
    PubMed     Abstract available


    January 2022
  91. HOSOYA S, Ueda K, Odajima S, Ogawa K, et al
    Scoring Systems of Peritoneal Dissemination for the Prediction of Operative Completeness in Advanced Ovarian Cancer.
    Anticancer Res. 2022;42:115-124.
    PubMed     Abstract available


  92. CARDENAS-GOICOECHEA J, Wang YU, Lee JH, Shoraka M, et al
    Survival After Minimally Invasive Surgery in Older Women With Endometrial Carcinoma.
    Anticancer Res. 2022;42:75-85.
    PubMed     Abstract available


  93. ACS M, Piso P, Prader S
    Current Status of Metastatic Cardiophrenic Lymph Nodes (CPLNs) in Patients With Ovarian Cancer: A Review.
    Anticancer Res. 2022;42:13-24.
    PubMed     Abstract available


  94. BISKUP E, Wils RS, Hogdall C, Hogdall E, et al
    Prospects of Improving Early Ovarian Cancer Diagnosis Using Cervical Cell Swabs.
    Anticancer Res. 2022;42:1-12.
    PubMed     Abstract available


  95. LEE J, Kim JM, Lee YH, Chong GO, et al
    Correlation Between Clinical Outcomes and Serum CA-125 Levels After Standard Treatment for Epithelial Ovarian Cancer.
    Anticancer Res. 2022;42:349-353.
    PubMed     Abstract available


  96. LEE EJ, Park SJ, Lee J, Mun J, et al
    The Clinical Desire for Pressurized Intraperitoneal Aerosol Chemotherapy in South Korea: An Electronic Survey-based Study.
    Anticancer Res. 2022;42:363-371.
    PubMed     Abstract available


    December 2021
  97. LEE J, Kim JM, Lee YH, Chong GO, et al
    Applicability of the Histoculture Drug Response Assay to Predict Platinum Sensitivity and Prognosis in Ovarian Cancer.
    Anticancer Res. 2021;41:6287-6292.
    PubMed     Abstract available


  98. CHECK JH, Check D
    New Insights as to Why Progesterone Receptor Modulators, such as Mifepristone, Seem to Be More Effective in Treating Cancers that Are Devoid of the Classical Nuclear Progesterone Receptor.
    Anticancer Res. 2021;41:5873-5880.
    PubMed     Abstract available


    November 2021
  99. ISONO R, Tsubamoto H, Ueda T, Takimoto Y, et al
    Itraconazole Inhibits Intracellular Cholesterol Trafficking and Decreases Phosphatidylserine Level in Cervical Cancer Cells.
    Anticancer Res. 2021;41:5477-5480.
    PubMed     Abstract available


    October 2021
  100. NOSAKA K, Suzuki S, Yoshikawa T, Shimomura M, et al
    Heat Shock Protein 105 as an Immunotherapeutic Target for Patients With Cervical Cancer.
    Anticancer Res. 2021;41:4741-4751.
    PubMed     Abstract available


  101. GADDUCCI A, Cosio S
    Randomized Clinical Trials and Real World Prospective Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review.
    Anticancer Res. 2021;41:4673-4685.
    PubMed     Abstract available


  102. LUENGAS-WUERZINGER V, Rawert F, CLAssEN-VON Spee S, Baransi S, et al
    Role of the Cardiophrenic Lymph Node Status After Neoadjuvant Chemotherapy in Primary Advanced Ovarian Cancer.
    Anticancer Res. 2021;41:5025-5031.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.